Intestinal Organoids (BIOÏDES)

Rennes University Hospital

Status: Enrolling

Conditions: Digestive System Diseases; Inflammatory Bowel Disease, Ulcerative Colitis Type; Crohn Disease

Treatments: Procedure: additional biopsies

Study type: Interventional

Funder types: Other

Identifiers

NCT05294107

35RC21_8862_BIOÏDES

Details and patient eligibility

About

Over the last decade, the use of mini-organ or organoids has been increasingly developed in fundamental research. Indeed, digestive organoids represent an essential advance compared to classical culture systems (epithelial cell lines, immortalized cells) since they preserve in culture the functional complexity present in vivo (architecture, different cell types). They also have the advantage of being able to be propagated indefinitely (unlike explants), minimizing the use of animal models and reducing the amount of tissue required. Finally, their growth and development depends on the origin of the sample (the organoid will develop differently if the cell source comes from a patient suffering from an inflammatory bowel disease, for example), thus generating models of human pathologies to better determine their physiopathology. The use of organoids in biomedical research has proven to be an indispensable tool for the understanding of cellular and molecular mechanisms involved in epithelial renewal and the screening of molecules and ingredients for applications in the health and agri-food sectors.

Full description

The project aims to generate a biocollection of 3D intestinal models from digestive biopsies with associated health data and to characterize them before using them for the screening of potential therapeutic molecules.

Enrollment: 90 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects aged 18 to 75 years
• Subject undergoing endoscopy as part of the standard of care with the need to take digestive biopsy samples
• Subject having signed a free and informed consent in writing

Exclusion criteria

• Subjects under legal protection (safeguard of justice, curatorship or guardianship) or deprived of liberty.
• Anticoagulant treatment and anti-platelet treatment (except for aspirin 75 mg)

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

90 participants in 3 patient groups

Group Crohn's disease

Experimental group

Description:

4 additional biopsies for 30 patients with Crohn's disease

Treatment:

Procedure: additional biopsies

Group ulcerative colitis

Experimental group

Description:

4 additional biopsies for 30 patients with ulcerative colitis

Treatment:

Procedure: additional biopsies

Group No MICI

Active Comparator group

Description:

4 additional biopsies for 30 patients out of Inflammatory Disease Chronic Bowel Disease

Treatment:

Procedure: additional biopsies